PD36-09 SACRAL NEUROMODULATION IN PARKINSON'S DISEASE: AN EFFECTIVE AVENUE OF TREATMENT

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Neurogenic Voiding Dysfunction (PD36)1 Sep 2021PD36-09 SACRAL NEUROMODULATION IN PARKINSON'S DISEASE: AN EFFECTIVE AVENUE OF TREATMENT Sarah Martin, Jacqueline Zillioux, Neil Kocher, Raymond Rackley, Sandip Vasavada, and Howard Goldman MartinSarah Martin More articles by this author , ZilliouxJacqueline Zillioux KocherNeil Kocher RackleyRaymond Rackley VasavadaSandip Vasavada GoldmanHoward View All Author Informationhttps://doi.org/10.1097/JU.0000000000002040.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Parkinson’s disease (PD) is the second-most common degenerative neurologic worldwide. Overactive bladder (OAB) prevalent in population but can be challenging treat due risks associated with polypharmacy (anticholinergics) difficulty self-catheterization cases retention (Onabotulinumtoxin-A). Sacral neuromodulation (SNM) an attractive treatment option, especially recent introduction MRI conditional technology, remains understudied PD. We utilized SNM PD patients for some time herein describe our outcomes. METHODS: performed a retrospective chart review who underwent peripheral nerve evaluation (PNE) or Stage 1 from 2000-2020. Primary outcome was progression permanent implant ≥50% improvement urinary symptoms. The impact stage pre-procedural urodynamic (UDS) parameters on test-phase assessed Fisher’s exact Wilcoxin rank sum tests. Long term efficacy using Wilcoxon matched-pairs test looking at change symptoms (frequency, nocturia, incontinence episodes, pad use) documented available follow-up visits further need treatment. RESULTS: 34 phase (7 PNE, 27 1). Mean age 72 (STD 7) years median 11 [IQR 5.8, 29.8] months. Indications included refractory OAB (30/34) non-obstructive (4/34). Overall, 82% (28/34) proceeded implant. 71% (5/7) PNEs were successful. Test-phase success did not differ based severity UDS parameters. In OAB/UUI progressed implant, 83% (24/28) experienced subjective their urgency there statistically significant baseline (Figure I). Most (68%) able discontinue medications post-implant, 62.5% require Overall lead revision rate 14% (4/28) 3 devices required removal. CONCLUSIONS: efficacious option high percentage having No found predict which would progress implantation. Source Funding: None © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e598-e599 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...